Coronavirus Update: End Of The Road For Hydroxychloroquine?
Plus Komipharm Pushes Ahead With Panaphix
UK investigators have pulled the plug on the drug trials, saying it is 'useless' in hospitalized COVID-19 patients - but the WHO is not giving up on its trial just yet.
You may also be interested in...
Regulators whipsawed by COVID-19-related drug shortages are seeking better ways to forecast demand.
US FDA's decision to revoke the COVID-19 emergency use authorization for two anti-malarial drugs keeps with commissioner Hahn's stated goal of moving fast to tackle the pandemic, but shifting course as new data comes available. FDA cited new evidence as well as a reanalysis of the data it initially based the EUA on as reasons for pulling the authorization. Meanwhile, HHS Secretary Alex Azar appeared to equate the EUA revocation as opening the doors for broader use of the medicine, potentially undermining FDA's own communication on the drug, in yet another example of political leaders complicating the science and public health response to COVID-19.
Vaccine developers worry that the focus on development speed may embolden anti-vaccine movement and hurt public willingness to get a COVID-19 shot if one is approved.